Biocracked
Approach 1, macro science, with Palette D, bold color field.

Extreme close-up microscopy-style photograph of a cluster of adipocytes (fat cells). Each is a translucent, pale yellow sphere with a thin membrane, and a few are shrunken and crinkled to suggest apoptosis. The cells sit against a saturated magenta backdrop. The camera is slightly above, at a shallow 30-degree angle, with a very shallow depth of field so the foreground cells are razor sharp and the rest melts into soft bokeh. Hard, clean side light from the left makes the membranes glisten and casts crisp magenta-tinted shadows. One tiny electric green fluorescent speck glows inside a single collapsing cell as a subtle accent. The mood is precise, clinical and curious, with a bold editorial feel. There is no text and no blue cast.
Research

CBL-514 Injection Lipolysis: A Phase 2 Map of the Evidence

Dr. Synapse · · 6 min read

CBL-514 Injection Lipolysis: A Phase 2 Map of the Evidence

CBL-514 is an investigational small-molecule injection designed to trigger fat-cell (adipocyte) apoptosis and shrink a treated pocket of abdominal fat. A 2025 single-blind, placebo-controlled Phase 2 trial in Aesthetic Surgery Journal randomized 76 people and reported large ultrasound-measured fat-volume losses versus saline, with no meaningful change in mean body weight. The results are interesting, but the design has real limits. This hub maps what the trial shows, what it cannot show, and where to go deeper.

Not medical advice. CBL-514 is investigational and is given by trial investigators, not self-administered.

What CBL-514 is (and is not)

The correct name is CBL-514. "CL-514" is a common typo. The compound comes from Caliway Biopharmaceuticals (New Taipei City, Taiwan). It is delivered as subcutaneous injections into a treated area, which in this study was the abdomen. It is not a supplement, not an oral pill, and not an approved consumer product. It is not FDA-approved as of the paper. The only FDA-approved injectable for fat reduction the paper mentions is ATX-101 (deoxycholic acid, Kybella), and that is only for submental (under-chin) fat.

The papers do not disclose the molecule's chemical structure, so there is no ingredient list to analyze.

The primary source is Gold M, Schlessinger J, Goodman GJ, Dayan S, DuBois J, Ling YF, Sheu AY, Ho WWS, Chou YC. Aesthet Surg J. 2025;45(6):611-620 (doi: 10.1093/asj/sjaf032; ClinicalTrials.gov NCT04897412). It is open access: https://pmc.ncbi.nlm.nih.gov/articles/PMC12080885/.

The proposed mechanism: company-reported, nonclinical

The earlier Phase 2a paper (Goodman et al., 2022) was smaller and open-label, with no placebo group. It states that nonclinical work showed CBL-514 inhibits the cell-survival kinase DYRK1b, upregulates the apoptosis mediators caspase 3 and Bax/Bcl-2, and induces dose-dependent adipocyte apoptosis in vitro and in vivo. Those mechanistic claims are cited to unpublished, confidential Caliway reports.

The mechanism is therefore a hypothesis from the sponsor's nonclinical work. It was not demonstrated in humans in this trial. It also describes local fat-cell death, not a higher metabolic rate, not calorie burning, and not whole-body weight loss. A biohacker's "fat-burning" framing is the wrong model here.

How the Phase 2 trial was built

  • Design: randomized, single-blind, parallel-group, placebo-controlled, run February 2022 to March 2023 at 5 centers in the US and Australia.
  • Randomization: 2:1 CBL-514 to placebo (normal saline).
  • Blinding: participants only, using visual barriers. Investigators, site staff and the sponsor, including the medical monitor, were unblinded. This is not a double-blind trial.
  • Sponsor role: Caliway was involved in study design, data collection, analysis and interpretation, manuscript writing, and the decision to submit.
  • Eligibility: ages 18-64, BMI above 18.5 and below 35, weight at least 50 kg, abdominal skinfold of 3-8 cm, and normal liver, renal, cardiovascular and immune function.
  • Weight stability rule: a deviation of 3 kg or more from baseline led to discontinuation.

Dose and schedule used in the trial

The dose was 2 mg/cm², with up to 600 mg per treatment. Each treatment involved 25 to 50 injections at the investigator's discretion, spaced 2.45 cm apart. Each injection delivered 2.4 mL of CBL-514 or an equivalent volume of saline. Participants received up to 4 treatments at 4-week intervals, then follow-up at 4 and 8 weeks after the final treatment. This is a trial protocol, not a consumer regimen.

How fat was measured

Fat was measured by ultrasound at four scan spots (4 and 10 cm to the right and left of an abdominal reference point). Three scans per point were averaged, and trained sonographers did the scanning. Volume was calculated as a cuboid: a defined 300 cm² treatment area multiplied by the average fat thickness. The authors also used 3D photography. The primary endpoint was the proportion of participants losing at least 150 mL at the 4- and 8-week follow-ups.

Who was actually in the data

130 people were screened, 81 enrolled and 76 randomized (50 CBL-514, 26 placebo). 75 were treated (49 CBL-514, 26 placebo). Of those 75, 38 completed the study and 37 did not, a non-completion rate of 49.3%. The reasons were loss to follow-up (6), participant withdrawal (7), weight instability (7), inability to keep the schedule (6) and adverse events (4).

The intention-to-treat (ITT) population was 76. The per-protocol (PP) population was only 30.

The CBL-514 group (n=50) averaged 46.3 years old, was 94% female and 86% White, with a mean BMI of 27.77. The placebo group was 80.8% female. The evidence applies mostly to women of moderate overweight with abdominal fat.

The efficacy numbers, with denominators

The authors say the trial met its primary endpoint and all secondary endpoints. The denominators shrink at follow-up because of missing visits, so read the percentages with that in mind.

At least 150 mL lost (ITT):

  • 4 weeks: CBL-514 63.9% (23/36; 95% CI 46.22%-79.18%) vs placebo 17.4% (4/23; 95% CI 4.95%-38.78%); P < .001.
  • 8 weeks: CBL-514 69.6% (16/23; 95% CI 47.08%-86.79%) vs placebo 0.0% (0/16); P < .001.

At least 200 mL lost (ITT):

  • 4 weeks: 58.3% (21/36; 95% CI 40.76%-74.49%) vs 8.7% (2/23; 95% CI 1.07%-28.04%); P < .001.
  • 8 weeks: 60.9% (14/23; 95% CI 38.54%-80.29%) vs 0.0% (0/16); P < .001.

Exploratory at least 250 mL: 44.4% (16/36) at 4 weeks and 52.2% (12/23) at 8 weeks in the CBL-514 group. No placebo participant reached it.

Mean change (ITT, least-squares): the between-group difference was −206.62 mL at 4 weeks (95% CI −276.09 to −137.16) and −216.28 mL at 8 weeks (95% CI −288.28 to −144.28), both P < .001.

PP population (30 people only): the between-group difference was −312.08 mL at 4 weeks and −276.83 mL at 8 weeks. This is a heavily filtered subset of completers, so it is likely to look more favorable than the ITT result.

Treatments needed: among the 28 CBL-514 participants who reached at least 150 mL, 12 did so after one treatment and 10 after two. That is 22 of 28 (about 79%) after one or two treatments. The largest single loss recorded was over 750 mL in one participant.

Weight did not change, which is the point

Mean body weight barely moved. CBL-514 participants showed +0.45 kg at the 4-week follow-up and +0.02 kg at 8 weeks, compared with −0.76 kg and −0.26 kg in the placebo group. The paper reports localized loss even in some participants who gained more than 1 kg (data not shown). That fits a local fat-volume effect, but it also means the scale is the wrong way to judge any benefit. It is not evidence of systemic fat burning.

Safety and limitations: read these before the headlines

Safety monitoring covered treatment-emergent adverse events, labs, vitals, ECGs, physical exams and injection-site reactions. Four participants withdrew because of adverse events. This hub does not reproduce the full adverse-event breakdown, so consult the paper's safety section for it.

Key limitations:

  • Single-blind only. Investigators and the sponsor knew who got what.
  • Sponsor involvement across design, analysis and publication.
  • High attrition. About half of treated participants did not complete, and the PP set was only 30.
  • Exploratory sample size with no formal power calculation, and no adjustment for multiple testing.
  • Short follow-up: 8 weeks after the last treatment, so durability is unknown.
  • Mostly women, so generalizing to men is weak.
  • Indirect comparisons. The authors compare results with cryolipolysis studies (for example, 264.8 mL at 12 weeks in one and 39.6 mL at 2 months in another) and call the CBL-514 outcome "comparable to that achieved with liposuction." These are the authors' interpretations. The methods differ, and no head-to-head trial exists.
  • Skin laxity was an impression from post-treatment images, not a formal endpoint.
  • Investigational status. It is not approved, and there is no self-injection protocol.

Explore the CBL-514 series

Bottom line

In this Phase 2 trial, CBL-514 produced a clear, statistically significant local reduction in ultrasound-measured abdominal fat volume versus saline, and body weight stayed flat. The mechanism comes from unpublished company nonclinical work. The evidence base is small, sponsor-involved, single-blind and short, with heavy dropout. It looks like a promising signal that needs larger, longer, better-blinded confirmation, not a settled result.

Original study

Read the original research on pmc.ncbi.nlm.nih.gov →

This article summarizes published research for general information. It is not medical advice.

DS

Written by

Dr. Synapse

Dr. Synapse writes for Biocracked: biohacking science, longevity & human performance.

Related Articles

**Approach 1 (macro science), Palette D (bold color field).**

Extreme close-up microscopy-style photograph of a cluster of fat cells (adipocytes), rendered as translucent, pearly spheres with thin membranes and tiny lipid droplets inside. One cell in the center is visibly shrinking and blebbing, its membrane crinkled and fragmenting into small beads, the look of apoptosis. A few of the surrounding cells are intact and glossy. The cells sit against a saturated tomato-red backdrop, so the pale yellow-cream spheres stand out sharply. The camera looks straight down at shallow depth of field, with the focal plane on the dying cell and the edges softly blurred. Soft, diffuse top light gives gentle highlights and warm shadows, with no blue cast. One thin electric green fluorescent ring around the central cell's nucleus is the only green accent. The mood is analytical, precise and quietly skeptical.
research

How does CBL-514 work? Here's the science

BY DR. SYNAPSE ·

CBL-514 is not framed as a fat-melting or fat-burning drug. The proposed claim is that it inhibits the survival kinase DYRK1b and pushes fat cells toward apoptosis through caspase 3 and Bax/Bcl-2. That evidence comes from unpublished company reports cited in the Phase 2a and Phase 2 papers, and the chemical structure has not been disclosed. The 2025 Phase 2 trial measured ultrasound fat volume, photos, and safety, with no human biopsy or caspase data. This article separates the molecular hypothesis from what was actually measured in people, including the high dropout and single-blind design.

Approach: the human outcome. Palette: bold color field.

A close, slightly high three-quarter view of a bare abdomen, cropped at the ribs and hips with no face. A hand in an electric green (#00e676) nitrile glove pinches a fold of belly skin and holds a slim syringe with the needle just about to enter. Faint yellow-purple bruising near the injection site hints at the side effects. The torso fills the frame against a flat, saturated teal backdrop that contrasts with the warm skin tones. Soft, even studio light from the left gives gentle shadows and visible skin texture, with fine pores and small hairs. The syringe tip is in sharp focus and the background falls away. No text or markings anywhere. The mood is clinical, unsentimental and skeptical.
research

Does CBL-514 really burn fat? Here's what we know

BY HELIX WARD ·

The 2025 Phase 2 CBL-514 trial did not test weight loss. It tested whether an abdominal injection could cut at least 150 mL of subcutaneous fat volume on ultrasound, and 69.6% (16/23) of treated participants got there at 8 weeks versus 0/16 on placebo. But mean body weight did not fall (+0.02 kg), nearly half of treated participants did not complete the study, and the per-protocol group was just 30 people. Injection-site reactions were common, including discoloration in 71.4% and severe pain in 18.4%. Here is the data-first breakdown of what the trial shows and what it doesn't.

Approach 2, lab in action, with palette D, bold color field.

Straight-on, slightly elevated close shot of a gloved hand in a pale nitrile glove holding a glass syringe with a fine needle. The syringe is filled with clear liquid and sits over a row of small glass vials in a matte white rack. The whole scene sits against a saturated tomato-red seamless backdrop. Soft, even studio light gives crisp highlights along the syringe barrel and the vial glass, plus gentle warm-red reflections on the surfaces. A thin electric green (#00e676) cap on one vial is the only small accent. The dosing markings on the syringe are blurred and unreadable. Shallow depth of field blurs the back vials into soft shapes. The mood is precise, clinical and investigational, with high contrast and a measured, careful feel. No text, no labels, no logos.
research

CBL-514 Dosages - what does science say?

BY DR. SYNAPSE ·

CBL-514 trials are investigational injection protocols, and the "600 mg" figure is a per-treatment cap, not a supplement dose. This article walks through the Phase 2a dose-finding study (1.2, 1.6 and 2.0 mg/cm² over 150 cm², n=43, open-label) and explains where the much-quoted 24.96% figure comes from. It then covers the placebo-controlled Phase 2, which kept 2.0 mg/cm² but doubled the area to 300 cm² and raised the cap to 600 mg. You will see why mg totals cannot be compared across studies, what safety was reported, and why this is still not approved or advice.

Approach 1, macro science, in palette D, bold color field.

Extreme close-up photograph of a cluster of fat cells (adipocytes) in tissue, shot like a stained microscopy image. Rounded, translucent, pearly-yellow lipid-filled cells press together in a honeycomb. Several in the center look collapsed and shriveled, with ruptured membranes and scattered droplets. A few fine threads of electric green (#00e676) fluorescent stain outline the cell walls. The camera is straight-on at shallow depth of field, with the background cells melting into soft blur. Bright, even transmitted light makes the membranes glow. The backdrop is a saturated magenta-to-tomato-red field that sets off the pale yellow cells. The mood is scrutinizing, skeptical and precise. No text, no labels.
research

CBL-514 fat removal injections: What does the science say?

BY DR. SYNAPSE ·

CBL-514 now has a placebo-controlled Phase 2 randomized trial in Aesthetic Surgery Journal, and the authors report it met its primary and secondary endpoints. But this appraisal shows why the design deserves a hard look: it was single-blind with unblinded investigators and sponsor, and the sponsor helped design, analyze and write the study. Of 75 treated participants, only 38 finished, and the per-protocol set was just 30 people. Follow-up ended 8 weeks after the final treatment, and the sample was mostly female and White. Here is what the trial can support, what it cannot, and why it is not medical advice or proof of an approved treatment.

This page is available in